,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca,Roche
['breast']
breast cancer #asco22
hamilton destiny-03 safety update of t-dm1 vs t-dxd. median t-dxd duration now 16 mo. ild/pneumonitis in 10.9% of t-dxd. nausea and vomiting greater with t-dxd, as was hair loss. no major new signals.
Professor of Medicine, Stanford University; breast cancer doc